Lena E Friberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3822255/publications.pdf

Version: 2024-02-01

168	7,357	53794 45	66911 78
papers	citations	h-index	g-index

173	173	173	6715
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2009, 53, 3430-3436.	3.2	448
2	Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs. Journal of Clinical Oncology, 2002, 20, 4713-4721.	1.6	436
3	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 391-400.	9.1	400
4	Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs. Pharmacological Reviews, 2013, 65, 1053-1090.	16.0	248
5	Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems. Antimicrobial Agents and Chemotherapy, 2013, 57, 5104-5111.	3.2	202
6	Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill. Antimicrobial Agents and Chemotherapy, 2012, 56, 4241-4249.	3.2	201
7	Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization. Antimicrobial Agents and Chemotherapy, 2011, 55, 4619-4630.	3.2	198
8	Irinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein. Clinical Pharmacology and Therapeutics, 2007, 81, 42-49.	4.7	164
9	A Review of Mixedâ€Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-10.	2.5	137
10	Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults. Antimicrobial Agents and Chemotherapy, 2012, 56, 3032-3042.	3.2	133
11	From Therapeutic Drug Monitoring to Modelâ€Informed Precision Dosing for Antibiotics. Clinical Pharmacology and Therapeutics, 2021, 109, 928-941.	4.7	131
12	Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia. Journal of Clinical Oncology, 2007, 25, 2719-2726.	1.6	115
13	Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes. Journal of the National Cancer Institute, 2004, 96, 1585-1592.	6.3	113
14	The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Medicine, 2017, 43, 1021-1032.	8.2	100
15	Dose response of whole-grain biomarkers: alkylresorcinols in human plasma and their metabolites in urine in relation to intake. American Journal of Clinical Nutrition, 2009, 89, 290-296.	4.7	97
16	A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients. Clinical Cancer Research, 2012, 18, 5780-5787.	7.0	96
17	Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 760-767.	2.8	94
18	Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 7240-7248.	3.2	93

#	Article	IF	Citations
19	CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity. Clinical Cancer Research, 2013, 19, 3316-3324.	7.0	88
20	Mechanistic models for myelosuppression. Investigational New Drugs, 2003, 21, 183-194.	2.6	87
21	Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Clinical Infectious Diseases, 2019, 69, 769-776.	5.8	83
22	Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities. Clinical Pharmacology and Therapeutics, 2015, 97, 37-54.	4.7	82
23	Population pharmacokineticâ€“pharmacodynamic modelling in oncology: a tool for predicting clinical response. British Journal of Clinical Pharmacology, 2015, 79, 56-71.	2.4	82
24	Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics Journal, 2011, 11, 113-120.	2.0	81
25	Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel. Clinical Cancer Research, 2012, 18, 4433-4440.	7.0	80
26	Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. British Journal of Clinical Pharmacology, 2006, 61, 177-190.	2.4	77
27	A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 591-601.	2.3	72
28	A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibodyâ€“Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer. AAPS Journal, 2014, 16, 994-1008.	4.4	72
29	Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates. Clinical Pharmacokinetics, 2009, 48, 253-263.	3.5	71
30	Pharmacokinetic-Pharmacodynamic Model for Gentamicin and Its Adaptive Resistance with Predictions of Dosing Schedules in Newborn Infants. Antimicrobial Agents and Chemotherapy, 2012, 56, 179-188.	3.2	71
31	Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2013, 57, 668-671.	3.2	71
32	The Population Pharmacokinetics of Citalopram After Deliberate Self-Poisoning: A Bayesian Approach. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 571-605.	1.8	65
33	Colistin Is Extensively Lost during Standard In Vitro Experimental Conditions. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	64
34	A CYP3A4 Phenotypeâ€“Based Dosing Algorithm for Individualized Treatment of Irinotecan. Clinical Cancer Research, 2010, 16, 736-742.	7.0	63
35	Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. Pediatric Research, 2013, 73, 68-74.	2.3	58
36	A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Investigational New Drugs, 2012, 30, 833-845.	2.6	57

#	Article	IF	Citations
37	Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia. Clinical Pharmacology and Therapeutics, 2009, 86, 84-91.	4.7	55
38	Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients. Clinical Pharmacokinetics, 2006, 45, 1099-1114.	3.5	54
39	A Pharmacokinetic and Dosing Study of Intravenous Insulin-Like Growth Factor-I and IGF-Binding Protein-3 Complex to Preterm Infants. Pediatric Research, 2009, 65, 574-579.	2.3	54
40	PKPD Modeling of VEGF, sVEGFRâ€2, sVEGFRâ€3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-9.	2.5	53
41	Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Medicine, 2006, 32, 1060-1065.	8.2	52
42	Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4â€“5 December 2014). CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 418-429.	2.5	52
43	Activated Charcoal Decreases the Risk of QT Prolongation After Citalopram Overdose. Annals of Emergency Medicine, 2007, 50, 593-600.e46.	0.6	48
44	Pharmacokinetics of Quetiapine in Overdose and the Effect of Activated Charcoal. Clinical Pharmacology and Therapeutics, 2007, 81, 821-827.	4.7	48
45	A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis. Clinical Pharmacology and Therapeutics, 2009, 86, 387-395.	4.7	48
46	Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	48
47	A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2015, 75, 791-803.	2.3	46
48	Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs. Pharmaceutical Research, 2016, 33, 1115-1125.	3.5	46
49	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: inÂvitro synergism is not associated with better clinical outcomes. Clinical Microbiology and Infection, 2020, 26, 1185-1191.	6.0	46
50	Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling. Pharmaceutical Research, 2014, 31, 3390-3403.	3.5	45
51	A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. Journal of Antimicrobial Chemotherapy, 2014, 69, 1350-1361.	3.0	44
52	PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinibâ€Treated Patients With GIST. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-9.	2.5	43
53	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open, 2016, 6, e009956.	1.9	41
54	Modelâ€Informed Drug Development for Antiâ€Infectives: State of the Art and Future. Clinical Pharmacology and Therapeutics, 2021, 109, 867-891.	4.7	41

#	Article	IF	Citations
55	Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model. Investigational New Drugs, 2010, 28, 744-753.	2.6	40
56	Predicting In Vitro Antibacterial Efficacy across Experimental Designs with a Semimechanistic Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 1571-1579.	3.2	40
57	Population Pharmacokinetics of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Recipients: New Initial Dosage Suggestions and a Model-Based Dosage Adjustment Tool. Therapeutic Drug Monitoring, 2009, 31, 457-466.	2.0	38
58	Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC). European Journal of Clinical Pharmacology, 2000, 56, 567-574.	1.9	37
59	Warfarin dose prediction in children using pharmacometric bridgingâ€"comparison with published pharmacogenetic dosing algorithms. European Journal of Clinical Pharmacology, 2013, 69, 1275-1283.	1.9	36
60	A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants. Journal of Antimicrobial Chemotherapy, 2015, 70, 3051-3060.	3.0	35
61	Dynamic interaction of colistin and meropenem on a WT and a resistant strain ofPseudomonas aeruginosaas quantified in a PK/PD model. Journal of Antimicrobial Chemotherapy, 2016, 71, 1279-1290.	3.0	35
62	Semi-mechanistic pharmacokineticâ€"pharmacodynamic modelling of antibiotic drug combinations. Clinical Microbiology and Infection, 2018, 24, 697-706.	6.0	35
63	Pharmacokinetic/Pharmacodynamic Modelling in Oncological Drug Development. Basic and Clinical Pharmacology and Toxicology, 2005, 96, 206-211.	2.5	34
64	A tool for neutrophil guided dose adaptation in chemotherapy. Computer Methods and Programs in Biomedicine, 2009, 93, 283-291.	4.7	34
65	Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy. Clinical Cancer Research, 2012, 18, 4425-4432.	7.0	34
66	Modelâ€Based Neutrophilâ€Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 234-242.	2.5	33
67	A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 69-79.	1.8	33
68	Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model. Drug Metabolism and Disposition, 2011, 39, 247-255.	3.3	32
69	The Effect of Decontamination Procedures on the Pharmacokinetics of Venlafaxine in Overdose. Clinical Pharmacology and Therapeutics, 2009, 86, 403-410.	4.7	29
70	Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2012, 69, 1155-1163.	2.3	29
71	Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	29
72	The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. Clinical Infectious Diseases, 2018, 67, 1815-1823.	5.8	29

#	Article	IF	Citations
73	Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2016, 48, 337-341.	2.5	28
74	Considerations for the optimal management of antibiotic therapy in elderly patients. Journal of Global Antimicrobial Resistance, 2020, 22, 325-333.	2.2	27
75	Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats. Cancer Chemotherapy and Pharmacology, 2000, 46, 493-500.	2.3	26
76	Simultaneous Exposureâ€"Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-11.	2.5	26
77	A pharmacokineticâ€"pharmacodynamic (PKPD) model based onin vitrotimeâ€"kill data predicts thein vivoPK/PD index of colistin. Journal of Antimicrobial Chemotherapy, 2016, 71, 1881-1884.	3.0	26
78	Evaluation of polymyxin B in combination with 13 other antibiotics against carbapenemase-producing Klebsiella pneumoniae in time-lapse microscopy and time-kill experiments. Clinical Microbiology and Infection, 2020, 26, 1214-1221.	6.0	26
79	Evaluation of IPPSE, an alternative method for sequential population PKPD analysis. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 177-193.	1.8	25
80	An Agonistâ€"Antagonist Interaction Model for Prolactin Release Following Risperidone and Paliperidone Treatment. Clinical Pharmacology and Therapeutics, 2009, 85, 409-417.	4.7	24
81	The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia. Cancer Chemotherapy and Pharmacology, 2012, 69, 881-890.	2.3	24
82	Pharmacokineticâ€"Pharmacodynamic Modeling of Severity Levels of Extrapyramidal Side Effects With Markov Elements. CPT: Pharmacometrics and Systems Pharmacology, 2012, 1, 1-9.	2.5	23
83	A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform. Clinical Cancer Research, 2013, 19, 5210-5217.	7.0	23
84	Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data. Journal of Antimicrobial Chemotherapy, 2017, 72, 3108-3116.	3.0	23
85	A <scp>PK/PD</scp> Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumabâ€Treated nonâ€small Cell Lung Cancer Patients. Clinical Pharmacology and Therapeutics, 2019, 105, 486-495.	4.7	23
86	Human methyl parathion poisoning. Clinical Toxicology, 2007, 45, 956-960.	1.9	22
87	Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Investigational New Drugs, 2011, 29, 984-995.	2.6	22
88	Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy. International Journal of Infectious Diseases, 2020, 92, 133-140.	3.3	22
89	Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria. Clinical Microbiology and Infection, 2020, 26, 1644-1650.	6.0	22
90	Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice. Clinical Microbiology and Infection, 2021, 27, 1315-1321.	6.0	21

#	Article	IF	Citations
91	Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemotherapy and Pharmacology, 2010, 65, 839-848.	2.3	20
92	Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer. British Journal of Clinical Pharmacology, 2016, 82, 717-727.	2.4	20
93	Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring. Cancer Chemotherapy and Pharmacology, 2017, 80, 343-353.	2.3	20
94	Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
95	Modelâ€Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin. Clinical Pharmacology and Therapeutics, 2021, 109, 1063-1073.	4.7	20
96	Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 543-551.	2.5	19
97	Pivotal Role of Translation in Antiâ€Infective Development. Clinical Pharmacology and Therapeutics, 2021, 109, 856-866.	4.7	19
98	Pharmacometrics and Systems Pharmacology 2030. Clinical Pharmacology and Therapeutics, 2020, 107, 76-78.	4.7	18
99	Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections. International Journal of Antimicrobial Agents, 2020, 56, 106059.	2.5	18
100	A Semiâ€Mechanistic Model of CPâ€690,550â€Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis. Journal of Clinical Pharmacology, 2010, 50, 679-687.	2.0	17
101	Characterizing variability in warfarin dose requirements in children using modelling and simulation. British Journal of Clinical Pharmacology, 2014, 78, 158-169.	2.4	17
102	Assessment of early combination effects of colistin and meropenem againstPseudomonas aeruginosaandAcinetobacter baumanniiin dynamic time-kill experiments. Infectious Diseases, 2017, 49, 521-527.	2.8	17
103	Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	17
104	Research priorities towards precision antibiotic therapy to improve patient care. Lancet Microbe, The, 2022, 3, e795-e802.	7.3	17
105	In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients. Cancer Letters, 2001, 162, 193-200.	7.2	16
106	PKâ€PD modeling of individual lesion FDGâ€PET response to predict overall survival in patients with sunitinibâ€treated gastrointestinal stromal tumor. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 173-181.	2.5	16
107	How preclinical infection models help define antibiotic doses in the clinic. International Journal of Antimicrobial Agents, 2020, 56, 106008.	2.5	16
108	A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 373-382.	2.5	15

#	Article	IF	Citations
109	A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6. PLoS ONE, 2019, 14, e0211981.	2.5	15
110	Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis. EBioMedicine, 2021, 73, 103652.	6.1	15
111	The pharmacokinetics of epirubicin and docetaxel in combination in rats. Cancer Chemotherapy and Pharmacology, 1999, 44, 469-474.	2.3	14
112	Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	14
113	Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection. Journal of Pharmaceutical Sciences, 2019, 108, 630-640.	3.3	14
114	Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout. AAPS Journal, 2015, 17, 245-255.	4.4	13
115	A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory. Pharmaceutical Research, 2018, 35, 122.	3.5	13
116	Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
117	Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data. International Journal of Antimicrobial Agents, 2020, 55, 105941.	2.5	13
118	Multistate model for pharmacometric analyses of overall survival in HER2â€negative breast cancer patients treated with docetaxel. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1255-1266.	2.5	13
119	Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology. AAPS Journal, 2018, 20, 39.	4.4	12
120	The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukinâ€6 and Câ€reactive protein by modelling. British Journal of Clinical Pharmacology, 2018, 84, 490-500.	2.4	12
121	Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?. Pediatric Blood and Cancer, 2019, 66, e27654.	1.5	12
122	Comparison of the agonistâ€antagonist interaction model and the pool model for the effect of remoxipride on prolactin. British Journal of Clinical Pharmacology, 2010, 70, 815-824.	2.4	11
123	Modelling the genesis and treatment of cancer: The potential role of physiologically based pharmacodynamics. European Journal of Cancer, 2010, 46, 21-32.	2.8	11
124	Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinibâ€Treated Patients With Gastrointestinal Stromal Tumors. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 449-457.	2.5	11
125	Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects. International Journal of Antimicrobial Agents, 2022, 60, 106616.	2.5	11
126	Pharmacokineticâ€“pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model. European Journal of Pharmaceutical Sciences, 2005, 25, 163-173.	4.0	10

#	Article	IF	Citations
127	Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. Clinical Infectious Diseases, 2020, 71, 2599-2607.	5.8	10
128	Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. Journal of Antimicrobial Chemotherapy, 2019, 74, 2984-2993.	3.0	9
129	Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2020, 26, 4590-4598.	7.0	8
130	Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic Pharmacokineticâ€“Pharmacodynamic Modeling for Evaluation of Treatments against Chronic Pseudomonas aeruginosa Lung Infections. Molecular Pharmaceutics, 2020, 17, 1458-1469.	4.6	8
131	Tumor Timeâ€Course Predicts Overall Survival in Nonâ€Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Followâ€Up Time. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 115-123.	2.5	8
132	Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2â€negative breast cancer patients treated with docetaxel. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 511-521.	2.5	8
133	A Wholeâ€Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 407-422.	2.5	7
134	Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia. International Journal of Antimicrobial Agents, 2022, 59, 106588.	2.5	7
135	Translational inÂvitro and inÂvivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia. Clinical Microbiology and Infection, 2022, 28, 1367-1374.	6.0	7
136	Inter occasion variability in individual optimal design. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 735-750.	1.8	6
137	Effects of cladribine tablets on heart rate, atrioâ€ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. British Journal of Clinical Pharmacology, 2019, 85, 1484-1494.	2.4	6
138	Acute bacterial or viral infectionâ€”What's the difference? A perspective from PKPD modellers. Clinical Microbiology and Infection, 2020, 26, 1133-1136.	6.0	6
139	Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors. Frontiers in Pharmacology, 2020, 11, 316.	3.5	6
140	CPT: Pharmacometrics & Systems Pharmacology â€“ Inception, Maturation, and Future Vision. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 649-657.	2.5	6
141	Bayesian Hierarchical Modeling with Markov Chain Monte Carlo Methods. , 0, , 137-164.		5
142	Reply to Dr. MÃ©garbane et al. regarding â€œPharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdoseâ€. Intensive Care Medicine, 2007, 33, 197-197.	8.2	5
143	Predictions of In Vivo Prolactin Levels from In Vitro K i Values of D2 Receptor Antagonists Using an Agonistâ€“Antagonist Interaction Model. AAPS Journal, 2013, 15, 533-541.	4.4	5
144	Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework. Clinical Cancer Research, 2020, 26, 4892-4900.	7.0	5

#	Article	IF	Citations
145	Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer. Frontiers in Pharmacology, 2021, 12, 759146.	3.5	5
146	Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. Journal of Antimicrobial Chemotherapy, 2022, 77, 934-943.	3.0	5
147	Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828. Drug Development Research, 2004, 61, 218-226.	2.9	4
148	Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli. International Journal of Antimicrobial Agents, 2018, 51, 399-406.	2.5	4
149	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. BMC Infectious Diseases, 2021, 21, 309.	2.9	4
150	Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance. Scientific Reports, 2022, 12, 4206.	3.3	4
151	Pharmacometrics and Systems Pharmacology Software Tutorials and Use: Comments and Guidelines for PSP Contributions. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 86.	2.5	3
152	Tutorials on the Foundations of Pharmacometrics and Systems Pharmacology. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-2.	2.5	2
153	Reply to Prim et al., â€œIs Colistin Susceptibility Testing Finally on the Right Track?â€• Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	2
154	Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel. Cancers, 2021, 13, 3915.	3.7	2
155	Continuous infusion of piperacillinâ€tazobactam significantly improves target attainment in children with cancer and fever. Cancer Reports, 2022, 5, e1585.	1.4	2
156	Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissueâ€“ Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations. Pharmaceutical Research, 2022, 39, 1633-1643.	3.5	2
157	Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. Clinical Cancer Research, 2022, 28, 1363-1371.	7.0	2
158	Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37, 493-506.	1.8	1
159	Acute organophosphorus poisoning in humans: A PK model for chlorpyrifos. Toxicology Letters, 2012, 211, S173.	0.8	1
160	CPT: Pharmacometrics & Systems Pharmacology Publishes Its 100th Article. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-2.	2.5	1
161	Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer. Cancers, 2019, 11, 173.	3.7	1
162	InÂvivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections. Clinical Microbiology and Infection, 2022, 28, 73-78.	6.0	1

#	Article	IF	Citations
163	PII-20Irinotecan (CPT-11) related diarrhea: Functional significance of the polymorphic ABCC2 transporter protein. Clinical Pharmacology and Therapeutics, 2006, 79, P41-P41.	4.7	0
164	Application of pharmacokinetic-pharmacodynamic modeling in management of QT abnormalities after citalopram overdose. Reply to A. Manini. Intensive Care Medicine, 2007, 33, 739-739.	8.2	0
165	CORRECTION TO â€œInfluence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Modelâ€: TABLE 3. Drug Metabolism and Disposition, 2011, 39, 563-563.	3.3	0
166	420 Increased Clearance of Docetaxel in Androgen Deprived Prostate Cancer Patients. European Journal of Cancer, 2012, 48, 128.	2.8	0
167	Reply to Wilson et al. Clinical Infectious Diseases, 2020, 71, 1358-1359.	5.8	0
168	Dr. Hartmut Derendorf, PhD, a worldâ€renowned expert in pharmacokinetics and pharmacometrics (1953â€“2020). CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 527-528.	2.5	0